You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
紫鑫藥業(002118.SZ)及子公司共有124個品種納入《國家醫保目錄(2019版)》
格隆匯 08-26 16:12

格隆匯8月26日丨紫鑫藥業(002118.SZ)公佈,近日,國家醫療保障局、人力資源社會保障部發布了《關於印發 <國家基本醫療保險、工傷保險和生育保險藥品目錄> 的通知》【醫保發[2019]46號】(“《國家醫保目錄(2019版)》”、“《醫保目錄》”)。現公司及控股子公司產品納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2019版)》的情況公告如下:

公司及控股子公司共有124個品種納入《國家醫保目錄(2019版)》,其中甲類62個,乙類62個,納入《國家醫保目錄(2019版)》的主要產品有:四妙丸、小活絡丸、養陰清肺糖漿等。

此次入選《醫保目錄》的124個產品中,乙類產品升甲類產品:6個、新進醫保產品:5個、退出醫保產品:4個、甲類產品降乙類產品:無。

公司多數重點產品納入在2019版國家醫保目錄內,這將有助於這些產品進一步的市場推廣和銷售,長期會對公司的經營業績產生一定積極影響。按照國家政府部門的相關配套管理辦法,入選目錄產品可能面臨價格調整的風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account